{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:56:21Z","timestamp":1793040981338,"version":"4.5.0"},"reference-count":31,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["Indian J Dermatol Venereol Leprol"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Though biologics have changed the therapeutic landscape in moderate-to-severe plaque psoriasis (PsO), their high cost is a major cause for restricted usage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the relative efficacy (psoriasis area severity index (PASI) 90\/100) and cost of biological agents available in India for moderate-to-severe PsO based on the cost per number needed to treat (NNT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>NNTs of biologicals derived from published network meta-analyses (NMA) for psoriasis area and severity index (PASI) 90 and 100, were used to calculate the cost per NNT by multiplying the NNT of a drug by the number of doses required and the corresponding market price in India. The calculated cost was based on the maximum retail price (MRP) at 12, 24, 52, and 104 weeks of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most economical drug based on MRP was ustekinumab (biosimilar). The cost per NNT (PASI 100) was lowest for ixekizumab at all time points, followed by ustekinumab. For PASI 90, the cost per NNT was lowest for ustekinumab at all time points, followed by ixekizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>NNT values from previously published NMA data were used. Cost-per-NNT analyses were based on randomised controlled trial (RCT) evidence and, thus, could not account for real-world factors that may impact the true cost of therapy. The cost of biologics varies due to the changes in the prices of the brands and the availability of biosimilars. Also, our analysis did not account for any adverse effects and their costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ixekizumab and ustekinumab were the most cost-effective biologics to achieve PASI 100 and PASI 90, as cost per NNT analysis. This data can be used by procurement agencies and dermatologists to estimate the cost to patients on short and long-term bases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/ijdvl_311_2025","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T06:54:07Z","timestamp":1756968847000},"page":"460-466","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A comparison of anti-IL-17A, anti-TNF, and anti-IL-12\/23 biologics for moderate-to-severe plaque psoriasis in India, based on cost per number needed to treat (NNT) and its effect on the therapeutic landscape and outcome"],"prefix":"10.25259","volume":"92","author":[{"given":"Kabir","family":"Sardana","sequence":"first","affiliation":[{"name":"Department of Dermatology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekhar","family":"Neema","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital, Cantonment, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devyani","family":"Sapra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital, Delhi Cantt., Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Jagadeesan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amrita Institute of Medical Sciences, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Muddebihal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. Ram Manohar Lohia Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"KB","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company India Pvt Ltd, Gurgaon, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Mistry","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company India Pvt Ltd, Gurgaon, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhina","family":"Das","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company India Pvt Ltd, Devarabisanahalli, Bangalore, Karnataka, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Base Hospital, Delhi Cantt., Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"10.25259\/IJDVL_311_2025\/ref-1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5114\/ada.2020.94832","article-title":"Pathogenesis of psoriasis in the \u201comic\u201d era Part I Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances","volume":"37","author":"Samotij","year":"2020","journal-title":"pdia"},{"key":"10.25259\/IJDVL_311_2025\/ref-3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.4103\/idoj.IDOJ_113_21","article-title":"Systemic management of psoriasis patients in indian scenario: An expert consensus","volume":"12","author":"Rajagopalan","year":"2021","journal-title":"Indian Dermatol Online J"},{"key":"10.25259\/IJDVL_311_2025\/ref-4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4103\/2229-5178.193906","article-title":"Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring","volume":"7","author":"Dogra","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"10.25259\/IJDVL_311_2025\/ref-5","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"10.25259\/IJDVL_311_2025\/ref-6","doi-asserted-by":"publisher","first-page":"228424031882228","DOI":"10.1177\/2284240318822289","article-title":"Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy","volume":"2019","author":"Ravasio","year":"2019","journal-title":"Glob & Reg Health Tech Technol Assess"},{"key":"10.25259\/IJDVL_311_2025\/ref-7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: A brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"10.25259\/IJDVL_311_2025\/ref-8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","article-title":"Biologics for psoriasis","volume":"42","author":"Wride","year":"2024","journal-title":"Dermatol Clin"},{"key":"10.25259\/IJDVL_311_2025\/ref-9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7365\/jhpor.2021.1.2","article-title":"Cost per responder analysis of biologics in moderate-to-severe plaque psoriasis in indian healthcare setting","author":"Gokhale","year":"2021","journal-title":"J Health Policy Outcomes Res"},{"key":"10.25259\/IJDVL_311_2025\/ref-10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/PTT.S375173","article-title":"Therapeutic inertia in the management of psoriasis: A quantitative survey among indian dermatologists and patients","volume":"12","author":"Rajagopalan","year":"2022","journal-title":"psoriasis (Auckl)"},{"key":"10.25259\/IJDVL_311_2025\/ref-11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PTT.S356568","article-title":"Biologics can significantly improve dermatology life quality index (DLQI) in psoriatic patients: A systematic review","volume":"12","author":"de Ruiter","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"10.25259\/IJDVL_311_2025\/ref-12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.36849\/jdd.2020.10.36849\/jdd.2020.4957","article-title":"Importance of complete skin clearance in psoriasis as a treatment goal: Implications for patient-reported outcomes","volume":"19","author":"Blauvelt","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.25259\/IJDVL_311_2025\/ref-13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s13555-021-00564-2","article-title":"Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: Pooled analysis from four phase 3 clinical trials of secukinumab","volume":"11","author":"Houghton","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_311_2025\/ref-14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2018.1401468","article-title":"The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis","volume":"14","author":"Frieder","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.25259\/IJDVL_311_2025\/ref-15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/jdv.14007","article-title":"Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: A systematic review and meta-analysis","volume":"31","author":"Puig","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_311_2025\/ref-16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.25259\/IJDVL_1006_19","article-title":"Pattern of use of biologics in psoriasis among Indian dermatologists \u2013 A cross sectional survey","volume":"88","author":"Neema","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_311_2025\/ref-17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"10.25259\/IJDVL_311_2025\/ref-18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: An introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.25259\/IJDVL_311_2025\/ref-19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: Explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.25259\/IJDVL_311_2025\/ref-20","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.vhri.2019.08.062","article-title":"PBI6 evaluation of biologic therapies for the treatment of moderate-to-severe plaque psoriasis in colombia: A cost per responder analysis (CPR)","volume":"19","author":"Gil-Rojas","year":"2019","journal-title":"Value Health Reg Issues"},{"key":"10.25259\/IJDVL_311_2025\/ref-26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.33393\/grhta.2021.2222","article-title":"Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy","volume":"8","author":"Ravasio","year":"2021","journal-title":"Grhta"},{"key":"10.25259\/IJDVL_311_2025\/ref-27","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jaad.2006.08.024","article-title":"Evidence-based dermatology: Number needed to treat and its relation to other risk measures","volume":"56","author":"Manriquez","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_311_2025\/ref-28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_311_2025\/ref-29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ad.2018.10.017","article-title":"A cost-per-number needed to treat analysis assessing the efficiency of biologic drugs in moderate to severe plaque psoriasis","volume":"110","author":"N\u00fa\u00f1ez","year":"2019","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas."},{"key":"10.25259\/IJDVL_311_2025\/ref-30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/ijd.ijd_420_23","article-title":"Disease assessment in psoriasis","volume":"68","author":"Manchanda","year":"2023","journal-title":"Indian J Dermatol"},{"key":"10.25259\/IJDVL_311_2025\/ref-31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.12817","article-title":"PASI 90 response: The new standard in therapeutic efficacy for psoriasis","volume":"29","author":"Puig","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_311_2025\/ref-32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","article-title":"Clinical meaningfulness of complete skin clearance in psoriasis","volume":"75","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_311_2025\/ref-33","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_311_2025\/ref-34","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","article-title":"Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis","volume":"14","author":"Augustin","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.25259\/IJDVL_311_2025\/ref-35","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.18553\/jmcp.2018.24.12.1210","article-title":"Cost-effectiveness of targeted pharmacotherapy for moderate to severe plaque psoriasis","volume":"24","author":"Hendrix","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"10.25259\/IJDVL_311_2025\/ref-36","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1080\/13696998.2017.1362413","article-title":"Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis","volume":"20","author":"Al Sawah","year":"2017","journal-title":"J Med Econ"},{"key":"10.25259\/IJDVL_311_2025\/ref-37","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ijdvl.com\/a-comparison-of-anti-il-17a-anti-tnf-and-anti-il-12-23-biologics-for-moderate-to-severe-plaque-psoriasis-in-india-based-on-cost-per-nnt-and-its-effect-on-the-therapeutic-landscape-and-outcome\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ijdvl.com\/a-comparison-of-anti-il-17a-anti-tnf-and-anti-il-12-23-biologics-for-moderate-to-severe-plaque-psoriasis-in-india-based-on-cost-per-nnt-and-its-effect-on-the-therapeutic-landscape-and-outcome\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:17:15Z","timestamp":1782562635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/a-comparison-of-anti-il-17a-anti-tnf-and-anti-il-12-23-biologics-for-moderate-to-severe-plaque-psoriasis-in-india-based-on-cost-per-nnt-and-its-effect-on-the-therapeutic-landscape-and-outcome\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":31,"alternative-id":["10.25259\/IJDVL_311_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_311_2025","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"article-number":"460"}}